Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lessened its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IARTFree Report) by 28.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 475,409 shares of the life sciences company’s stock after selling 190,823 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Integra LifeSciences were worth $20,704,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in IART. Raymond James & Associates increased its position in Integra LifeSciences by 24.5% during the 1st quarter. Raymond James & Associates now owns 40,457 shares of the life sciences company’s stock worth $2,600,000 after purchasing an additional 7,971 shares in the last quarter. MetLife Investment Management LLC increased its position in Integra LifeSciences by 33.4% during the 1st quarter. MetLife Investment Management LLC now owns 47,096 shares of the life sciences company’s stock worth $3,026,000 after purchasing an additional 11,796 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in Integra LifeSciences by 10.5% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 26,696 shares of the life sciences company’s stock worth $1,715,000 after purchasing an additional 2,546 shares in the last quarter. Great West Life Assurance Co. Can grew its holdings in Integra LifeSciences by 8.0% in the 1st quarter. Great West Life Assurance Co. Can now owns 40,012 shares of the life sciences company’s stock valued at $2,643,000 after buying an additional 2,969 shares during the period. Finally, Yousif Capital Management LLC grew its holdings in Integra LifeSciences by 6.5% in the 1st quarter. Yousif Capital Management LLC now owns 40,207 shares of the life sciences company’s stock valued at $2,584,000 after buying an additional 2,466 shares during the period. Institutional investors and hedge funds own 84.78% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on IART. Truist Financial lowered their price target on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a report on Friday, March 1st. StockNews.com cut Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Tuesday, March 12th. JMP Securities lowered their price target on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a report on Thursday, February 29th. Finally, Wells Fargo & Company upgraded Integra LifeSciences from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $40.00 to $49.00 in a report on Tuesday, December 5th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $45.00.

Check Out Our Latest Research Report on Integra LifeSciences

Integra LifeSciences Stock Performance

Integra LifeSciences stock opened at $34.83 on Thursday. The stock’s 50 day moving average price is $39.63 and its 200 day moving average price is $39.73. The firm has a market capitalization of $2.72 billion, a PE ratio of 41.96, a price-to-earnings-growth ratio of 1.01 and a beta of 1.13. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45. Integra LifeSciences Holdings Co. has a one year low of $33.24 and a one year high of $59.33.

Integra LifeSciences (NASDAQ:IARTGet Free Report) last announced its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The business had revenue of $397.00 million during the quarter, compared to analyst estimates of $399.30 million. During the same period in the previous year, the company earned $0.94 earnings per share. The business’s revenue for the quarter was down .3% on a year-over-year basis. As a group, sell-side analysts expect that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current fiscal year.

Integra LifeSciences Profile

(Free Report)

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

Featured Stories

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. (NASDAQ:IARTFree Report).

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.